Tag - Sellas

SELLAS Life Sciences Group (NASDAQ:SLS) completed enrollment for a Phase 2 study of nelipepimut-S (NPS) in combination with granulocyte macrophage colony stimulating factor (GM-CSF) in women with ductal carcinoma in...